Use of Reticulocyte Ratio and Neutrophil / Lymphocyte Ratio in the Diagnosis of Ventilator-associated Pneumonia

Ventilator-associated Pneumonia (VAP) Clinical Trial

Official title:

Use of Reticulocyte Ratio and Neutrophil / Lymphocyte Ratio in the Diagnosis of Ventilator-associated Pneumonia

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04620941
• Other study ID #: 27/12/2019-19/XI
• Status: Suspended
• Start date: February 21, 2020
• Est. completion date: September 21, 2023

Study information

• Verified date: January 2022
• Source: Mugla Sitki Koçman University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

In this study, the utility of changes in the ratio of Ret-He and NLR as an early inflammation marker for VAP will be evaluated.

Description:

Ventilator-associated pneumonia (VAP) is one of the most common nosocomial infections in the intensive care unit, affecting one third of patients requiring mechanical ventilation for a noninfectious reason. In the case of inflammation, iron retention increases in the reticuloendothelial system cells; hemoglobin (Hb) synthesis is reduced. It has been reported that the ratio of reticulocyte / hemoglobin (Ret-He) decreases in the early period in community-acquired pneumonia patients and may be a guide as a marker of inflammation. In addition, the neutrophil / lymphocyte ratio (NLR) is a parameter studied in the hemogram panel. It provides a clue to both the presence of infection and the focus of the infection. In this study, the utility of changes in the ratio of Ret-He and NLR as an early inflammation marker for VAP will be evaluated.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 35
• Est. completion date: September 21, 2023
• Est. primary completion date: July 21, 2023
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

-Patients who need mechanical ventilation for longer than 48 hours for a noninfectious reason in the intensive care unit

Exclusion Criteria:

• Pulmonary or extrapulmonary infection before mechanical ventilation,
• severe immunosuppression,
• bleeding in the gastrointestinal system,
• using corticosteroids,
• neoplastic disease history

Related Conditions & MeSH terms

• Pneumonia
• Pneumonia, Ventilator-Associated
• Ventilator-associated Pneumonia (VAP)

Intervention

Diagnostic Test:
• reticulocyte/hemoglobin (Ret-He) ratio
Ret-He values will be studied on the day (1st day), 4th and 7th days of the diagnosis of ventilator-associated pneumonia in patients hospitalized in the intensive care unit.

Locations

Country	Name	City	State
Turkey	Mugla Sitki Kocman Universty	Mugla	Kötekli

Sponsors (1)

Lead Sponsor	Collaborator
Mugla Sitki Koçman University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Early inflammation markers for VAP	To investigate the use of NLR and Ret-He value as early inflammation markers for VAP.	7 days
Secondary	morbidity and mortality	To compare the effects of Ret-He and NLR values on morbidity and mortality with other inflammation markers	7 days